Unraveling the Link between Glycerol-3-Phosphate and Fibroblast Growth Factor-23 in ESKD [0.03%]
终末期肾病患者磷代谢异常的机制研究进展
Angelina Dixon,Jessica Kendrick
Angelina Dixon
Finerenone and eGFR slope across Different Levels of Baseline Albuminuria and Estimated Glomerular Filtration Rate: Insights from FINEARTS-HF [0.03%]
芬戈莫德和不同基线白蛋白尿及估算肾小球滤过率水平下的eGFR斜率：来自FINEARTS-HF研究的见解
Finnian R Mc Causland,Hiddo J L Heerspink,Muthiah Vaduganathan et al.
Finnian R Mc Causland et al.
Background: Finerenone did not modify the risk of kidney outcomes or estimated glomerular filtration rate (eGFR) decline among patients with heart failure (HF) in the FINEARTS-HF trial, who were generally at low risk for ...
A Randomized Clinical Trial of Kidney Autologous Cell Therapy in Diabetic Kidney Disease [0.03%]
糖尿病肾病自体细胞治疗的随机临床试验
Čižman Borut,Emily L Butler,Joseph Stavas et al.
Čižman Borut et al.
Background: Despite new treatments to delay disease progression in patients with diabetes and chronic kidney disease (CKD), many patients continue to lose kidney function and progress to kidney failure. Additional therape...
Comparing Age and Sex Specific Reference Values of Estimated Glomerular Filtration Rate between the United States and Europe [0.03%]
美国和欧洲CKD流行病学合作网的估算肾小球滤过率的参考值比较
Megan E Astley,Alberto Ortiz,Stein Hallan et al.
Megan E Astley et al.
The extent to which estimated glomerular filtration rate (eGFR) varies across populations, in the absence of risk factors and comorbidities associated with kidney disease, remains uncertain. We aimed to develop eGFR reference values in heal...
Multiomic Immune Profiling of Pediatric Transplant Recipients Identifies Cell States Associated with Vaccine Response [0.03%]
儿童移植受者的多组学免疫特征鉴定与疫苗反应相关的细胞状态
Johannes Wedel,Ying Tang,Bayan Alsairafi et al.
Johannes Wedel et al.
Background: Immunosuppressive therapy following solid organ transplantation inhibits protective immunity to pathogens and vaccines. However, the specific cell states associated with failure to generate responsiveness to v...
Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis [0.03%]
补体介导的原发性C3肾小球病和免疫复合物介导的膜增生性肾小球肾炎的自然史及长期临床转归分析
Giliane Nanchen,Maddalena Marasà,Matteo Breno et al.
Giliane Nanchen et al.
Background: Membranoproliferative glomerulonephritides (MPGNs) are defined by a typical glomerular histopathological pattern including C3 glomerulopathy (C3G) and immune complex-mediated MPGN (IC-MPGN). The overall progno...
Real-World Hospitalization Outcomes with On-Line Hemodiafiltration versus High-Flux Hemodialysis: A Retrospective, International Cohort Study [0.03%]
在线血液透析滤过与高通量血液透析的住院结局：回顾性国际队列研究
Yan Zhang,Anke Winter,Linda H Ficociello et al.
Yan Zhang et al.
Background: Patients with end stage kidney disease undergoing hemodialysis (HD) experience high rates of hospitalizations and mortality, partly due to the incomplete removal of some toxic uremic molecules. To improve outc...
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated Focal Segmental Glomerulosclerosis Enrolled in the DUPLEX Trial [0.03%]
DUPLEX试验中遗传性局灶节段性肾小球硬化的患者接受斯帕森坦治疗的抗蛋白尿作用
Jennifer Yee,Wu Gong,Jula Inrig et al.
Jennifer Yee et al.
Background: Focal segmental glomerulosclerosis (FSGS) is a podocytopathy that is diagnosed based on characteristic histopathological lesions. Certain forms of FSGS with underlying genetic variants associated with the dise...
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy [0.03%]
PROTECT试验中舒塞替尼治疗IgA肾病的完全尿蛋白缓解与肾脏功能之间的关系：第3阶段临床试验结果
Hiddo Jl Heerspink,Brad H Rovin,Radko Komers et al.
Hiddo Jl Heerspink et al.
Background: In the phase 3, randomized, double-blind PROTECT (NCT03762850) trial, sparsentan, a single-molecule dual endothelin angiotensin receptor antagonist (DEARA), reduced proteinuria and preserved kidney function co...